Neumora TherapeuticsNMRA
NMRA
About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees: 110
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
221% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 14
29% more funds holding
Funds holding: 103 [Q3] → 133 (+30) [Q4]
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
6.88% more ownership
Funds ownership: 42.85% [Q3] → 49.72% (+6.88%) [Q4]
4% more call options, than puts
Call options by funds: $64.8M | Put options by funds: $62.2M
6% less capital invested
Capital invested by funds: $906M [Q3] → $852M (-$54M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
28%
upside
Avg. target
$6
669%
upside
High target
$18
2,208%
upside
5 analyst ratings
2 positive
40%
2 neutral
40%
1 negative
20%
Needham Ami Fadia 22% 1-year accuracy 35 / 159 met price target | 541%upside $5 | Buy Reiterated | 10 Apr 2025 |
B of A Securities Geoff Meacham 45% 1-year accuracy 15 / 33 met price target | 28%upside $1 | Underperform Downgraded | 2 Apr 2025 |
Stifel Paul Matteis 13% 1-year accuracy 2 / 15 met price target | 156%upside $2 | Hold Downgraded | 7 Mar 2025 |
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target | 2,208%upside $18 | Buy Reiterated | 7 Mar 2025 |
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 69 met price target | 413%upside $4 | Sector Perform Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 70 articles about NMRA published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m.
Neutral
Accesswire
3 weeks ago
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Neutral
Accesswire
3 weeks ago
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141583&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
3 weeks ago
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) and certain of its officers.
Neutral
GlobeNewsWire
3 weeks ago
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
3 weeks ago
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRA
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.
Neutral
Accesswire
3 weeks ago
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141539&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Business Wire
3 weeks ago
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Neutral
Accesswire
3 weeks ago
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class Action - NMRA
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141431&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
3 weeks ago
FINAL REMINDER NMRA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Neumora Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit
NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Charts implemented using Lightweight Charts™